Corvus Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Ph…

Biotechnology
US, Burlingame [HQ]
Strategy & Leadership

Mergers & Acquisitions Beta

M&A Deals · Breakdown

Corvus Pharmaceuticals, Inc. has no acquisition track records yet.

M&A Deals · History

Corvus Pharmaceuticals, Inc. has no acquisition track records yet.

End of CRVS's Analysis
CIK: 1626971 CUSIP: 221015100 ISIN: US2210151005 LEI: - UEI: -
Secondary Listings
CRVS has no secondary listings inside our databases.